Colorectal Polyps
Conditions
Keywords
colorectal polyps
Brief summary
This study aims to evaluate the efficacy of Chanyanning granules in patients undergoing endoscopic resection of colorectal polyps with a basal diameter of 5-30 mm. From one day before the procedure to five days postoperatively, patients will be administered Chanyanning granules. The study will observe intraoperative and postoperative bleeding, perforation, and digestive system-related clinical symptoms such as postoperative abdominal pain, bloating, diarrhea, constipation, hematochezia, and fatigue, as well as related inflammatory markers, to determine the therapeutic effect of Chanyanning granules.
Interventions
DRUGchangyanning granules
From one day before the procedure to five days postoperatively, patients in the experimental group will be administered Chanyanning granules.
DRUGPlacebo
control
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with colorectal polyps through endoscopic examination and who received corresponding endoscopic treatments (EMR, hybrid ESD, ESD).
Exclusion criteria
* Concurrent infectious diseases or malignant tumors; Accompanied by severe cardiopulmonary diseases (such as severe heart failure, COPD, etc.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidence of complications | From enrollment to the end of treatment at 2 weeks | The incidence of complications (blood in stool, perforation) and postoperative discomfort symptoms (abdominal pain, abdominal distension, diarrhea, constipation, fatigue, fever, etc.) were compared between the experimental group and the control group (primary endpoints). |
| C-reactive protein | From enrollment to the end of treatment at 2 weeks | — |
| erythrocyte sedimentation rate | From enrollment to the end of treatment at 2 weeks | — |
| serum interleukin-6 | From enrollment to the end of treatment at 2 weeks | — |
| white blood cells | From enrollment to the end of treatment at 2 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| hospitalization costs | From enrollment to the end of treatment at 2 weeks |
| hospital stay | From enrollment to the end of treatment at 2 weeks |
Countries
China
Outcome results
None listed